Da Jan Yang
Directeur Général chez ASCENTAGE PHARMA GROUP INTERNATIONAL
Profil
Da Jan Yang is the founder of Ascentage Pharma Group International Co., Ltd.
(founded in 2009) and Ascenta Therapeutics, Inc. (California) (founded in 2004).
At Ascentage Pharma Group International Co., Ltd., Dr. Yang holds the title of Chairman & Chief Executive Officer.
Dr. Yang's current job(s) include being the Chairman & Chief Executive Officer at Suzhou Ascentage Pharma Co., Ltd., Director at Ascentage Pharma Group, Inc., Director at Jiangsu Ascentage Pharma Pty Ltd., Director at Ascentage International Ltd., Director at Shanghai Yasheng Pharmaceutical Technology Co., Ltd., and Director at Ascentage Pharma Group Corp.
Ltd.
Dr. Yang's former job(s) include being the Vice President-Biology at S*BIO Pte Ltd.
from 2002 to 2003, Member-Supervisory Board & Professor at Sun Yat-Sen University from 2003 to 2006, and President of The Chinese Biopharmaceutical Association from 2005 to 2006.
Dr. Yang's education history includes a doctorate degree from Michigan State University in 1992, an undergraduate degree from Sun Yat-Sen University in 1983, and a graduate degree from Sun Yat-Sen University in 1986.
Postes actifs de Da Jan Yang
| Sociétés | Poste | Début |
|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Directeur Général | 01/05/2009 |
Ascentage Pharma Group Corp. Ltd.
 Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang. | Directeur/Membre du Conseil | - |
| Ascentage International Ltd. | Directeur/Membre du Conseil | - |
| Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | Directeur/Membre du Conseil | - |
| Ascentage Pharma Group, Inc. | Directeur/Membre du Conseil | - |
| Jiangsu Ascentage Pharma Pty Ltd. | Directeur/Membre du Conseil | - |
Ascentage Pharma Suzhou Co Ltd
 Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Suzhou Ascentage Pharma Co., Ltd. is a pharmaceutical company. Suzhou Ascentage Pharma Co., Ltd. is based in Suzhou, China. The Chinese company was founded in 2016 by Guang Feng Wang. The CEO is Da Jan Yang. | Directeur Général | - |
Anciens postes connus de Da Jan Yang
| Sociétés | Poste | Fin |
|---|---|---|
| Ascenta Therapeutics, Inc. (California) | Directeur Général | 01/01/2008 |
| Sun Yat-Sen University | Directeur/Membre du Conseil | 01/09/2006 |
| ░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Da Jan Yang
| Michigan State University | Doctorate Degree |
| Sun Yat-Sen University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Health Technology |
| Entreprise privées | 9 |
|---|---|
| Ascenta Therapeutics, Inc. (California) | |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
| The Chinese Biopharmaceutical Association | |
| Ascentage Pharma Group, Inc. | |
| Jiangsu Ascentage Pharma Pty Ltd. | |
| Ascentage International Ltd. | |
| Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | |
Ascentage Pharma Suzhou Co Ltd
Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Suzhou Ascentage Pharma Co., Ltd. is a pharmaceutical company. Suzhou Ascentage Pharma Co., Ltd. is based in Suzhou, China. The Chinese company was founded in 2016 by Guang Feng Wang. The CEO is Da Jan Yang. | Health Technology |
Ascentage Pharma Group Corp. Ltd.
Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang. | Health Technology |
